Premium
Senti Biosciences Inc (SNTI)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Senti Biosciences Inc is engaged in creating new generation smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Biosciences Inc is engaged in creating new generation smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches.
– Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced in June 2024 – – Cash runway guidance extended into 2026...
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) – SOUTH SAN...
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and...
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing...
– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile – – Dose escalation is continuing with...
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing...
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and...
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and...
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.07 | 1.81347150259 | 3.86 | 4.7699 | 3.775 | 86932 | 4.31423949 | CS |
| 4 | -1.665 | -29.7587131367 | 5.595 | 5.88 | 3.5 | 125309 | 4.37531055 | CS |
| 12 | 1.79 | 83.6448598131 | 2.14 | 16.94 | 2.08 | 2533218 | 9.64614008 | CS |
| 26 | 0.92 | 30.5647840532 | 3.01 | 16.94 | 1.5201 | 1162517 | 9.37054924 | CS |
| 52 | -1.241 | -23.9992264552 | 5.171 | 16.94 | 1.5201 | 2428028 | 5.30643764 | CS |
| 156 | -70.77 | -94.7389558233 | 74.7 | 87.7 | 1.5201 | 1888727 | 14.79938494 | CS |
| 260 | -70.77 | -94.7389558233 | 74.7 | 87.7 | 1.5201 | 1888727 | 14.79938494 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
